Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?
The DOI matches its Crossref record; 289 of the 289 references it cites were found in a registry or an index.
Abstract
The nuclear factor-kappaB (NF-κB) signaling pathway is considered as a potential therapeutic target in cancer therapy. It has been well established that transcription factor NF-κB is involved in regulating physiological and pathological events including inflammation, immune response and differentiation. Increasing evidences suggest that deregulated NF-κB signaling can enhance cancer cell proliferation, metastasis and also mediate radio-as well as chemo-resistance. On the contrary, non-coding RNAs (ncRNAs) have been found to modulate NF-κB signaling pathway under different settings. MicroRNAs (miRNAs) can dually inhibit/induce NF-κB signaling thereby affecting the growth and migration of cancer cells. Furthermore, the response of cancer cells to radiotherapy and chemotherapy may also be regulated by miRNAs. Regulation of NF-κB by miRNAs may be mediated via binding to 3/-UTR region. Interestingly, anti-tumor compounds can increase the expression of tumor-suppressor miRNAs in inhibiting NF-κB activation and the progression of cancers. Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) can also effectively modulate NF-κB signaling thus affecting tumorigenesis. Noteworthy, several studies demonstrate that lncRNAs and circRNAs can affect miRNAs in targeting NF-κB activate. They can act as competing endogenous RNA (ceRNA) thereby reducing miRNA expression to induce NF-κB activation that can enhance cancer progression and malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
9 retracted
Items 201–289 of 289
Khalife, J., Ghose, J., Martella, M., Viola, D., Rocci, A., Troadec, E., Terrazas, C. A., Satoskar, A. R., Gunes, E. G., Donà, A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129348 · Cited by 50
Dong, H., Liu, Q., Zhao, T., Yao, F., Xu, Y., Chen, B., Wu, Y., Zheng, X., Jin, F., Li, J., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.12.016 · Cited by 50
Abdelfatah, S., Böckers, M., Asensio, M., Kadioglu, O., Klinger, A., Fleischer, E., & Efferth, T. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153196 · Cited by 48
Circular RNA GLIS2 promotes colorectal cancer cell motility via activation of the NF-κB pathway
Chen, J., Yang, X., Liu, R., Wen, C., Wang, H., Huang, L. J., Li, W., Zhu, Z., Zhu, Y., & Liu, H. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02989-7 · Cited by 48
Huang, T., Zhang, X., & Wang, H. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11304 · Cited by 48
Wang, Y., Jiang, F., Jiao, K., Ju, L., Liu, Q., Li, Y., Miao, L., & Li, Z. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111739 · Cited by 47
Qiu, S., Chen, G., Peng, J., Liu, J., Chen, J., Wang, J., Li, L., & Yang, K. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12833 · Cited by 47
Wu, X., Chen, H., Wu, M., Peng, S., & Zhang, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-5192 · Cited by 46
Mohan, C. D., Bharathkumar, H., Dukanya, Rangappa, S., Shanmugam, M. K., Chinnathambi, A., Alharbi, S. A., Alahmadi, T. A., Bhattacharjee, A., Lobie, P. E., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01125 · Cited by 46
Self-citationHsa_circ_0009910: oncogenic circular RNA targets microRNA-145 in ovarian cancer cells
Li, Y., Lin, S., & An, N. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1731650 · Cited by 46
Ni, F., Gui, Z., Guo, Q., Hu, Z., Wang, X., Chen, D., & Wang, S. (2015) · Oncology Letters · doi:10.3892/ol.2015.3993 · Cited by 46
Liao, Z., Zhao, J. L., & Yang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8782 · Cited by 45
Wang, L., Jiang, F., Ma, F., & Zhang, B. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-019-00522-w · Cited by 44
Gehringer, F., Weissinger, S. E., Mӧller, P., Wirth, T., & Ushmorov, A. (2019) · Leukemia · doi:10.1038/s41375-019-0628-0 · Cited by 44
Zhao, B., Wang, Y., Tan, X., Ke, K., Zheng, X., Wang, F., Lan, S., Liao, N., Cai, Z., Shi, Y., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.08.009 · Cited by 43
Xiang, S., Zou, P., Wu, J., Zheng, F., Tang, Q., Zhou, J., & Hann, S. S. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490028 · Cited by 43
Liu, B., Cao, W., & Ma, H. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1626404 · Cited by 43
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Self-citationShen, X., Zhao, W., Zhang, Y., & Liang, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s220306 · Cited by 42
Xu, Q., Lin, Y., Li, L., & Liu, J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.087 · Cited by 42
miR‑126/VCAM‑1 regulation by naringin suppresses cell growth of human non‑small cell lung cancer
Chen, M., Peng, W., Hu, S., & Deng, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9204 · Cited by 41
Dai, X., Mao, F., Li, S., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7007 · Cited by 40
Tumor Suppressor Function of miR-127-3p and miR-376a-3p in Osteosarcoma Cells
Fellenberg, J., Lehner, B., Sähr, H., Schenker, A., & Kunz, P. (2019) · Cancers · doi:10.3390/cancers11122019 · Cited by 40
miR-423 Promotes Breast Cancer Invasion by Activating NF-κB Signaling
Dai, T., Zhao, X., Li, Y., Yu, L., Li, Y., Zhou, X., & Gong, Q. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s236514 · Cited by 39
Jiao, Y., Yang, H., Qian, J., Gong, Y. L., Liu, H., Wu, S., Cao, L., & Tang, L. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4680 · Cited by 38
Qureshi, A. A., Zuvanich, E. G., Khan, D. A., Mushtaq, S., Silswal, N., & Qureshi, N. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0697-5 · Cited by 38
Anilkumar, N. C., Mohan, C. D., Rangappa, S., Ananda, H., Sukhorukov, A. Y., Shanmugam, M. K., Sundaram, M. S., Nayaka, S. C., Girish, K. S., Chinnathambi, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163209 · Cited by 38
Self-citationLi, T., Li, M., Xu, C., Xu, X., Ding, J., Cheng, L., & Ou, R. (2019) · Oncology Reports · doi:10.3892/or.2019.7046 · Cited by 38
Huang, F., Peng, J., Cheng, W., Zhuang, Y., Wang, L., Li, C.-Q., Tang, J., Chen, W., Li, Y., & Zhang, S. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4472-7 · Cited by 37
Nie, Z.-Y., Zhao, M., Cheng, B.-Q., Pan, R., Wang, T., Qin, Y., & Zhang, X.-J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01468-5 · Cited by 35
Li, Y., Pei, F., & Cao, M. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8600 · Cited by 34
Wang, Y., Lei, X., Gao, C., Xue, Y., Li, X., Wang, H., & Feng, Y. (2019) · Journal of Biosciences · doi:10.1007/s12038-019-9952-9 · Cited by 34
Hou, J., Zhuo, H., Chen, X., Cheng, J. R., Zheng, W., Zhong, M., & Cai, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.40338 · Cited by 33
miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1
Gong, H., Fang, L., Li, Y., Du, J., Zhou, B., Wang, X., Zhou, H., Gao, L.-L., Wang, K., & Zhang, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6199 · Cited by 33
Yang, X., Ye, J., Han, Y., Tang, Z., Shen, J., Zhang, J., & Yang, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-3687-5 · Cited by 33
Liu, F., Cheng, L., Xu, J., Guo, F., & Chen, W. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4543 · Cited by 32
MiR-506-3p suppresses papillary thyroid cancer cells tumorigenesis by targeting YAP1
Chen, L., Wang, X., Ji, C., Hu, J., & Fang, L. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153231 · Cited by 32
Wang, Q., Wang, Z., Chu, L., Xu, L., Kan, P., Xin, X., Zhu, Y. T., & Yang, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125473 · Cited by 32
Qian, Y., Wu, X., Wang, H., Hou, G., Han, X., & Wei, S. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20209330 · Cited by 32
Ding, H., Cui, L., & Wang, C. (2020) · Neurological Research · doi:10.1080/01616412.2020.1836465 · Cited by 32
Xie, X., Xu, Z., Xu, K., & Xiao, Y. (2019) · Neurological Research · doi:10.1080/01616412.2019.1685068 · Cited by 31
Jin, L., Zhou, Y., Han, L., & Piao, J. (2019) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00417-5 · Cited by 31
Faria, M., Matos, P., Pereira, T., Cabrera, R., Cardoso, B. A., Bugalho, M. J., & Silva, A. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172689 · Cited by 31
Tao, F., Xu, Y., Yang, D., Tian, B., Jia, Y., Junming, H., & Dong, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27300 · Cited by 31
Jiang, J., & Cheng, X. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1815147 · Cited by 30
Liu, K., Song, J., Yan, Y., Zou, K., Che, Y., Wang, B., Li, Z., Yu, W., Guo, W., Zou, L., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100876 · Cited by 30
You, S., He, X., Wang, M., Mao, L., & Zhang, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s256347 · Cited by 30
Hafez, H. M., & Hassanein, H. (2020) · Drug and Chemical Toxicology · doi:10.1080/01480545.2020.1730885 · Cited by 30
Han, X., Wei, L., & Wu, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239730 · Cited by 30
Hong, L., Wang, H., Wang, J., Wei, S., Zhang, F., Han, J., Liu, Y., Ma, M., Liu, C., Xu, Y. G., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s231369 · Cited by 29
Mehta, A. K., Hua, K. L., Whipple, W. J., Nguyen, M.-T., Liu, C., Haybaeck, J., Weidhaas, J. B., Settleman, J., & Singh, A. (2017) · Science Signaling · doi:10.1126/scisignal.aam6291 · Cited by 28
Chen, B.-C., Tu, S., Zheng, B., Dong, Q.-J., Wan, Z.-A., & Dai, Q. (2020) · Bioscience Reports · doi:10.1042/bsr20200203 · Cited by 28
Yu, X., Ding, H., Yang, L., Yu, Y., Zhou, J., Yan, Z., & Guo, J. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23080 · Cited by 28
Lin, Y., Chen, Z., Zheng, Y., Liu, Y., Gao, J., Lin, S., & Chen, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00266 · Cited by 28
Jayaganesh, R., Pugalendhi, P., & Murali, R. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22441 · Cited by 28
Li, C.-L., Huang, C., KO, C.-J., Fang, S., Ou‐Yang, F., Pan, M., Luo, C., & Hou, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14565 · Cited by 28
LncRNA ROR1‑AS1 high expression and its prognostic significance in liver cancer
Zhang, Z., Wang, S., Yang, F., Meng, Z., & Liu, Y. (2019) · Oncology Reports · doi:10.3892/or.2019.7398 · Cited by 25
A Role for the NF-κB Pathway in Cell Protection from Complement-Dependent Cytotoxicity
Gancz, D., Lusthaus, M., & Fishelson, Z. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103451 · Cited by 25
Zhang, L. M., Li, S., Hu, J., Wang, D., Ju, H., Li, X., Han, Y., Xia, W., Guo, W., Ren, G., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03057-w · Cited by 25
LINC02163 promotes colorectal cancer progression via miR-511-3p/AKT3 axis
Ma, J., Zhang, L., Shang, A., Hu, S., Huo, J., Zhang, M., & Jiang, L. (2020) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2020.1773486 · Cited by 24
Feng, Q., Zhang, H., Nie, X., Li, Y., Chen, W., & Wang, Y. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.10.010 · Cited by 23
Pan, S., Hu, Y., Hu, M., Xu, Y., Chen, M., Du, C., Cui, J., Zheng, P., Lai, J., Zhang, Y., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4907 · Cited by 23
Zhao, M., Chang, J., Liu, R., Liu, Y., Qi, J., Wang, Y., Zhang, X., Qiao, L., Yu, J. H., An, H., et al. (2020) · 癌症:英文版 · doi:10.1002/cac2.12076 · Cited by 22
miR-484 is associated with disease recurrence and promotes migration in prostate cancer
Lee, D., Tang, W., Dorsey, T. H., & Ambs, S. (2020) · Bioscience Reports · doi:10.1042/bsr20191028 · Cited by 22
Yan, S., Cheng, M., Duan, Q., Wang, Z., Gao, W., Ren, B., & Xu, D. (2019) · Mediators of Inflammation · doi:10.1155/2019/8128501 · Cited by 22
Zhang, C., Wang, J., Zhang, J., Qu, H., & Tang, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247776 · Cited by 22
MiR-411 inhibits gastric cancer proliferation and migration through targeting SETD6.
Tl, B., Yb, L., & Bh, L. (2019) · PubMed · doi:10.26355/eurrev_201904_17697 · Cited by 21
Yang, X., Sun, Y., Zhang, Y., & Han, S. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4720 · Cited by 21
A Novel Three-lncRNA Signature Predicts the Overall Survival of HNSCC Patients
Jiang, H., Ma, B., Xu, W., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09210-1 · Cited by 21
miR-27a Downregulation Promotes Cutaneous Squamous Cell Carcinoma Progression via Targeting EGFR
Wang, Y., Deng, X., Dai, Y., Niu, X., & Zhou, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01565 · Cited by 21
miR‑629 targets FOXO3 to promote cell apoptosis in gastric cancer
Li, M., Wang, Y., Liu, X., Zhang, Z., Wang, L., & Li, Y. H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8168 · Cited by 20
Liu, B., Wang, Z., Cheng, S., Du, L., Yin, Y., Yang, Z., & Zhou, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10362 · Cited by 20
Jing, P., Zhou, S., Xu, P., Cui, P. L., Liu, X., Liu, X., Liu, X., Wang, H., & Xu, W. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111746 · Cited by 20
Sun, S., Shu, Y.-G., & Tao, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s222681 · Cited by 19
Schizandrin A inhibits cellular phenotypes of breast cancer cells by repressing miR ‐155
Yan, H., & Guo, M. (2020) · IUBMB Life · doi:10.1002/iub.2329 · Cited by 19
p53 and NFκB: fresh breath in the cross talk
Tergaonkar, V. (2009) · Cell Research · doi:10.1038/cr.2009.132 · Cited by 18
Self-citationFan, X.-D., Luo, Y., Wang, J., & An, N. (2020) · Bioscience Reports · doi:10.1042/bsr20193158 · Cited by 18
Zhao, Y., Tang, X., Huang, Y., Tang, Q., Ma, C., Zheng, F., Wu, W., & Hann, S. S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s226830 · Cited by 18
Zhu, D., Shi, Z., Fang, C., Guo, X., Han, D., Tang, M., Fu, H., Jiang, M., Xie, N., Nie, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.033 · Cited by 17
miR ‐497 induces apoptosis by the IRAK2 / NF‐κB axis in the canine mammary tumour
Zhang, T., Feng, X., Zhou, T., Zhou, N., Shi, X., Zhu, X., Qiu, J., Deng, G., & Qiu, C. (2020) · Veterinary and Comparative Oncology · doi:10.1111/vco.12626 · Cited by 17
Egan, S. M., Karasik, E., Ellis, L., & Gollnick, S. O. (2017) · Oncotarget · doi:10.18632/oncotarget.18795 · Cited by 15
Wang, H., Jiang, F., Liu, W., & Tian, W. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152899 · Cited by 14
Liu, Z., Hou, J., Ren, L., He, J., Sun, B., Sun, L., & WANG, S. (2015) · Oncology Reports · doi:10.3892/or.2015.3772 · Cited by 13
miR‑218 inhibits glucose metabolism in non‑small cell lung cancer via the NF‑κB signaling pathway
Tian, W., Yuan, X., Song, Y.-N., Zhai, J., Wei, H., Wang, L., Li, D., & Chen, Q. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9538 · Cited by 12
Wang, Z., Liang, X., Xiong, A., Ding, L., Li, W., Yang, L., Wu, X., Shi, H., Zhou, Y., & Wang, Z. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4882 · Cited by 12
MiR-425 Promotes Migration and Invasion in Bladder Cancer by Targeting Dickkopf 3
Ning, J., Yu, W., Fan, C., Rao, T., & Ruan, Y. (2020) · Journal of Cancer · doi:10.7150/jca.40233 · Cited by 11
Quinn, J. A., Bennett, L., Patel, M., Frixou, M., Park, J. H., Roseweir, A. K., Horgan, P. G., McMillan, D., & Edwards, J. (2020) · PubMed · doi:10.14670/hh-18-168 · Cited by 6
Sun, B., Xing, K., Qi, C., Yan, K., & Xu, Y. (2020) · PubMed · doi:10.14670/hh-18-278 · Cited by 3
p53 and NFκB: fresh breath in the cross talk
Vinay, & Tergaonkar (2009) · Cited by 1
Cited by
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Self-citationNF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
Entezari, M., Hashemi, D., Taheriazam, A., Zabolian, A., Mohammadi, S., Fakhri, F., Hashemi, M., Hushmandi, K., Ashrafizadeh, M., Zarrabi, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112563 · Cited by 400
Self-citationRetractedMirzaei, S., Saghari, S., Bassiri, F., Raesi, R., Zarrabi, A., Hushmandi, K., Sethi, G., & Tergaonkar, V. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30759 · Cited by 243
“The lncRNAs can reduce miRNA expression via sponging (Ashrafizadeh, Zarrabi, Hushmandi, Hashemi et al., 2020).”
BackgroundInfluentialSelf-citationHashemi, M., Zandieh, M. A., Talebi, Y., Rahmanian, P., Shafiee, S. S., Nejad, M. M., Babaei, R., Sadi, F. H., Rajabi, R., Abkenar, Z. O., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114392 · Cited by 117
Self-citationRetracted
Metadata
- Authors
- Mirzaei, S., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Ranjbar, A., Seyed Saleh, S. H., Bagherian, M., Sharifzadeh, S. O., Hushmandi, K., Liskova, A., Kubatka, P., Makvandi, P., Tergaonkar, V., Kumar, A. P., Ashrafizadeh, M., & Sethi, G.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 509
- Pages
- 63-80
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W3149058386
- Cited by
- 224
- References
- 289
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.